- Onco-Innovations’ (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium
- The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology
- AstraZeneca’s EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research
- Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23
This content has been prepared in collaboration with Onco-Innovations Ltd., a third-party issuer, and is intended for informational purposes only.
Onco-Innovations’ (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium.
The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology. The initiative seeks to address challenges in translational modeling, particularly during the transition from early- to late-stage clinical development, by integrating insights from pharmaceutical, data science, and clinical research sectors.
AstraZeneca’s EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research. The company’s involvement in the exploratory phase will include joint planning, early input into project direction, and strategic alignment on key use cases.
Inka Health is still ready to mingle with other global pharmaceutical companies regarding participation in the Consortium and plans to provide further updates as these discussions progress.
The PROmAI initiative will leverage a wide range of multimodal data—including molecular, clinical, and imaging datasets—combined with emerging techniques in causal AI. The goal is to foster innovation in predictive oncology, improve transparency in AI applications, and support frameworks that align with both regulatory and payer expectations.
For Inka Health, the Consortium represents a strategic opportunity to lead the development of next-generation AI tools in oncology. The company’s proprietary platform, SynoGraph, utilizes causal inference to identify patient subgroups most likely to respond to specific treatments, thereby supporting precision medicine and optimizing clinical trial design.
Onco-Innovations views AstraZeneca’s interest as a strong endorsement of the Consortium’s potential to shape the future of oncology research and drug development.
“This is not just about proving that AI can work in oncology-it’s about shaping how it should work in ways that matter to regulators, clinicians, and ultimately patients. Having AstraZeneca engage at this early stage signals a shared commitment to advancing practical, credible AI applications in one of medicine’s most complex domains,” Paul Arora, CEO of Inka Health, said in a news release. “As leaders in this space, we see PROmAI not only as a research initiative but as a foundation for setting standards around trust, utility, and translational impact in oncology-focused AI.”
Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology.
Onco-Innovations (CBOE CA:ONCO) closed 12.06 per cent higher on Friday at C$2.23.
Join the discussion: Find out what everybody’s saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
